Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
siRNA
Biotech
Atrium arises from Avidity buyout with $270M, preclinical assets
Atrium hopes to have two siRNA candidates for genetic cardiac diseases in the clinic by 2027.
Darren Incorvaia
Feb 27, 2026 11:05am
GSK explores frontiers of siRNA with $1B deal for 2 drugs
Feb 24, 2026 8:10am
Madrigal pens $4.4B deal for siRNA drugs in fresh Rezdiffra play
Feb 11, 2026 7:40am
Wave, Structure stocks double on obesity data readouts
Dec 8, 2025 10:50am
Sarepta shares safety update on DM1 RNA med
Nov 24, 2025 4:00pm
GSK pens $750M deal for COPD-focused oligonucleotide in phase 1
Oct 28, 2025 6:45am
